Literature DB >> 20654591

Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition.

Sarah K Kidd1, Jay S Schneider.   

Abstract

Although the pathophysiological processes involved in dopamine (DA) neuron degeneration in Parkinson's disease (PD) are not completely known, apoptotic cell death has been suggested to be involved and can be modeled in DAergic cell lines using the mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP(+)). Recently, it has been suggested that histone deacetylase inhibitors (HDACIs) may reduce apoptotic cell death in various model systems. However, their utility in interfering with DA cell death remains unclear. The HDACIs sodium butyrate (NaB), valproate (VPA) and suberoylanilide hydroxamic acid (SAHA) were tested for their ability to prevent MPP(+)-mediated cytotoxicity in human derived SK-N-SH and rat derived MES 23.5 cells. All three HDACIs at least partially prevented MPP(+)-mediated apoptotic cell death. The protective effects of these HDACIs coincided with significant increases in histone acetylation. These results suggest that HDACIs may be potentially neuroprotective against DA cell death and should be explored further in animal models of PD. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20654591      PMCID: PMC2941155          DOI: 10.1016/j.brainres.2010.07.041

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  29 in total

1.  Histochemical detection of apoptosis in Parkinson's disease.

Authors:  H Mochizuki; K Goto; H Mori; Y Mizuno
Journal:  J Neurol Sci       Date:  1996-05       Impact factor: 3.181

2.  n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells.

Authors:  M G Riggs; R G Whittaker; J R Neumann; V M Ingram
Journal:  Nature       Date:  1977-08-04       Impact factor: 49.962

3.  Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.

Authors:  C J Phiel; F Zhang; E Y Huang; M G Guenther; M A Lazar; P S Klein
Journal:  J Biol Chem       Date:  2001-07-25       Impact factor: 5.157

Review 4.  Oxidative stress in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

5.  Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway.

Authors:  Hoon Ryu; Junghee Lee; Beatrix A Olofsson; Aziza Mwidau; Alpaslan Dedeoglu; Maria Escudero; Erik Flemington; Jane Azizkhan-Clifford; Robert J Ferrante; Rajiv R Ratan; Alpaslan Deodoglu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

Review 6.  The role of glial reaction and inflammation in Parkinson's disease.

Authors:  E C Hirsch; T Breidert; E Rousselet; S Hunot; A Hartmann; P P Michel
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

Review 7.  MPTP: insights into parkinsonian neurodegeneration.

Authors:  Samuel G Speciale
Journal:  Neurotoxicol Teratol       Date:  2002 Sep-Oct       Impact factor: 3.763

8.  Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration.

Authors:  Caroline Rouaux; Natasa Jokic; Corinne Mbebi; Stephanie Boutillier; Jean-Philippe Loeffler; Anne-Laurence Boutillier
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

9.  HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells.

Authors:  Yong Wang; Xuan Wang; Limin Liu; Xiaomin Wang
Journal:  Neurosci Lett       Date:  2009-10-14       Impact factor: 3.046

10.  Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat.

Authors:  H Mochizuki; N Nakamura; K Nishi; Y Mizuno
Journal:  Neurosci Lett       Date:  1994-03-28       Impact factor: 3.046

View more
  36 in total

Review 1.  Epigenetic regulation in Parkinson's disease.

Authors:  Catherine Labbé; Oswaldo Lorenzo-Betancor; Owen A Ross
Journal:  Acta Neuropathol       Date:  2016-06-29       Impact factor: 17.088

2.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Authors:  Erin M Hill-Burns; Justine W Debelius; James T Morton; William T Wissemann; Matthew R Lewis; Zachary D Wallen; Shyamal D Peddada; Stewart A Factor; Eric Molho; Cyrus P Zabetian; Rob Knight; Haydeh Payami
Journal:  Mov Disord       Date:  2017-02-14       Impact factor: 10.338

3.  Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.

Authors:  Ian F Harrison; William R Crum; Anthony C Vernon; David T Dexter
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

4.  Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice.

Authors:  Janitza L Montalvo-Ortiz; Daniel W Fisher; Guadalupe Rodríguez; Deyu Fang; John G Csernansky; Hongxin Dong
Journal:  Psychopharmacology (Berl)       Date:  2017-04-18       Impact factor: 4.530

5.  Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease.

Authors:  R St Laurent; L M O'Brien; S T Ahmad
Journal:  Neuroscience       Date:  2013-04-25       Impact factor: 3.590

6.  Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult.

Authors:  Louise M Collins; Luc J Adriaanse; Surabhi D Theratile; Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-07-29       Impact factor: 5.590

7.  A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study.

Authors:  Jacopo Troisi; Annamaria Landolfi; Carmine Vitale; Katia Longo; Autilia Cozzolino; Massimo Squillante; Maria Cristina Savanelli; Paolo Barone; Marianna Amboni
Journal:  Metabolomics       Date:  2019-06-10       Impact factor: 4.290

8.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

9.  Developmental exposure to the organochlorine insecticide endosulfan damages the nigrostriatal dopamine system in male offspring.

Authors:  W Wyatt Wilson; Lauren P Shapiro; Joshua M Bradner; W Michael Caudle
Journal:  Neurotoxicology       Date:  2014-08-02       Impact factor: 4.294

10.  Exposure to the polybrominated diphenyl ether mixture DE-71 damages the nigrostriatal dopamine system: role of dopamine handling in neurotoxicity.

Authors:  Joshua M Bradner; Tiffany A Suragh; W Wyatt Wilson; Carlos R Lazo; Kristen A Stout; Hye Mi Kim; Min Z Wang; Douglas I Walker; Kurt D Pennell; Jason R Richardson; Gary W Miller; W Michael Caudle
Journal:  Exp Neurol       Date:  2012-12-31       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.